[The family demographic policy in the context of population reproduction: the country-specific review].

The purpose of the study is to systematize theoretical models of demographic family policy approved in publications included into database SCOPUS in 2019-2020 and developed using empirical data obtained by analysis of methods and practices of increasing natality in certain countries of EU, BRICS and the New World. The France, Sweden, Great Britain, Norway and Denmark are oriented to expand measures of social support of citizen and regulation of occupation of women with children with purpose to increase natality. In the countries of South-Western Asia and North Africa the measures are targeted to decreasing level of natality and to implement family planning policy.

[The Common Partner of Several Methyltransferases Modifying the Components of The Eukaryotic Translation Apparatus].

TRM112 is necessary for the activation and stability of several methyltransferases involved in the modification of various components of the translation apparatus. This unique protein is a partner for enzymes that methylate tRNA, rRNA, and the translation termination factor. Here we review the structural and functional features of the TRM112 complexes with methyltransferases and provide, where possible, information on their significance.

Effects of peroxisome proliferator activated receptors-alpha and -gamma agonists on estradiol-induced proliferation and hyperplasia formation in the mouse uterus.

It is suggested that the action of peroxisome proliferator-activated receptors (PPARs) cross-talks with estrogen signaling in the uterus. However, it is not known how PPAR agonists affect estrogen-dependent processes in the uterus, especially proliferation and morphogenetic changes. The effects of agonists of PPAR-alpha and -gamma on proliferative and morphogenetic reactions in the uterus under short- and long-term estrogen treatments were therefore examined. Ovariectomized mice were treated with estradiol dipropionate (4 micro g/100 g, s.c., once a week) or vehicle and rosiglitazone (PPAR-gamma agonist) or fenofibrate (PPAR-alpha agonist) or with no additional treatment for 2 days or for 30 days. Treatment with estradiol and PPAR agonists for 2 days did not affect uterine mass. In mice treated with estradiol and rosiglitazone for 2 days, proliferation was enhanced and levels of estrogen receptors-alpha and beta-catenin were decreased in all uterine tissues. Treatment with estradiol and fenofibrate for 2 days had the opposite effects on the parameters tested. In animals treated with estradiol and rosiglitazone for 30 days, uterine mass was increased, abnormal uterine glands and atypical endometrial hyperplasia were found more often and levels of estrogen receptors-alpha and beta-catenin were decreased. In animals treated with estradiol and fenofibrate for 30 days, uterine mass was decreased, most of the uterine glands had a normal structure, no cases of atypical hyperplasia were diagnosed, proliferative activity was declined and the levels of estrogen receptors-alpha and beta-catenin were markedly higher. Treatment with rosiglitazone or fenofibrate did not affect the serum estradiol level in the mice which received estradiol together with PPAR agonists for 30 days. Thus, rosiglitazone exerted the proliferative and morphogenetic effects of estradiol, but fenofibrate had the opposite effect. The actions of rosiglitazone and fenofibrate are associated with changes in the expression of estrogen receptors-alpha and beta-catenin in the uterus.